Standard concurrent chemoradiotherapy (CCRT) for cervical cancer achieves disease-free survival (DFS) in approximately 70% of patients with locally advanced disease; however, nearly 30% still experience recurrence or metastasis.
Standard concurrent chemoradiotherapy (CCRT) for cervical cancer achieves disease-free survival (DFS) in approximately 70% of patients with locally advanced disease; however, nearly 30% still experience recurrence or metastasis.
© 2024 SheSpeaks.ca - Your Voice, Your Story.